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Since the number of the autologous remnant cardiac progenitor cells and the mobilized cells form the bone marrow 
upon injury signal are too low, as well as the own myocyte proliferation rate is insuffi cient for complete recovery of the 
heart after ischemic injury, external regenerative cells are implanted into the injured heart to promote the regenera-
tion process. Accordingly, the clinical cardiac regeneration treatment with the intention to improve clinical symptoms, 
quality of life, and LV performance, as well as prevention of hospitalization, reduction of mortality and morbidity came 
into the forefront of pre-clinical and clinical investigations in the last 15 years. The majority of the heart failure clini-
cal cell-based cardiac regeneration studies included patients with low ejection fraction (<40%), and applied the cells 
(mostly bone-marrow, or mesenchymal stem cells) percutaneously intramyocardially. Most studies and meta-analyses 
resulted in moderate improvement of the left ventricular function and quality of life, however, the last three randomized 
trials failed to reach the primary effi cacy endpoints. To enhance the effectiveness of the regeneration therapy in heart 
failure, cell-free therapy with paracrine factors, including exosomes and cell function modulators, such as noncoding 
RNAs came into foreground. 
Klinikai sejtalapú kardiális regenerációs kezelés az iszkémiás szívelégtelenségben szenvedö betegekben
Ismert, hogy az autológ kardiális progenitor sejtek és a myocadium sérülés hatására a csontvelőből mobilizált sejtek 
száma túl alacsony és a cardiomyocyták saját proliferációs képessége nem elegendő a szív iszkémiás károsodásának 
teljes regenerálásához. Teoretikusan, reparatíve sejtek sérült myocardiumba való implantálása elösegítheti a rege-
neráció folyamatát. Ennek megfelelően az elmúlt 15 évben a klinikai tünetek, az életminőség és a balkamra-funkció 
javítását, a hospitalizáció megelőzését és a mortalitás valamint a morbiditás csökkentését célzó kardiális regenerációs 
kezelés a preklinikai és klinikai vizsgálatok élvonalába került. A szívelégtelenségben végzett sejtalapú, klinikai, kardiális 
regenerációs vizsgálatok többségében alacsony bal kamra ejekciós frakciójú (LVEF<40%) betegek kerültek besoro-
lásra és az alkalmazott sejtek elsősorban csontvelői eredetű, vagy mesechymalis őssejtek voltak, amelyeket percutan 
intramyocardialisan alkalmaztak. A legtöbb vizsgálat és metaanalízis a balkamra-funkció és az életminőség mérsékelt 
javulását mutatta, a legutóbbi három randomizált vizsgálat azonban nem igazolt kedvező változást a primer effektivi-
tási végpontokat illetően. Szívelégtelenségben a regenerációs terápia hatásosságának javítása céljából a sejtmentes 
kezelési alternatívák, így parakrin faktorok többek között exosomák, sejtfunkció-modulátorok pl. nem kódoló RNS-ek 
alkalmazása került előtérbe.
szívelégtelenség, sejtalapú kardiális regenerációs kezelés, sejt-mentes regenerációs terápia, klinikai vizsgálatKulcsszavak:
Keywords: heart failure, cell-based cardiac regeneration therapy, cell-free therapy, clinical studies
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Introduction
The incidence of ischemic heart failure (HF) caused by 
coronary artery disease (CAD) is increasing due to suc-
cessful reduction of acute complications of myocardial 
infarction and improved survival. Those patients are ty-
pically left with reduced left ventricular (LV) with sub-
sequent chronic heart failure symptoms. The availab-
le therapeutic options are limited to medical treatment 
to improve their symptoms, apart from device therapy/
heart transplantation in serious cases. Since the num-
ber of the autologous remnant cardiac progenitor cells 
and the mobilized cells form the bone marrow upon in-
jury signal are too low, as well as the own myocyte pro-
liferation rate is insuffi cient for complete recovery of the 
heart after ischemic injury, external regenerative cells 
are implanted into the injured heart to promote the re-
generation process. Accordingly, the cardiac regenera-
tion treatment with the intention to improve clinical sy-
mptoms, quality of life, and LV performance, as well as 
prevention of hospitalization, reduction of mortality and 
morbidity came into the forefront of pre-clinical and cli-
nical investigations in the last 15 years. 
Cells used for cardiac regeneration 
in ischemic HF
At the beginning of the cell-based regenerative thera-
py, unselected mixed cells of bone marrow origin were 
used in clinical trials for cardiac repair, because of a 
lack of information about which cell type would be best 
suited. Most bone marrow cells belong to hematopoi-
etic and lymphatic lineage and produce mature blood 
cells. Other bone marrow cell types are also present, 
which, however, are undesirable in the areas of myo-
cardial injury, such as osteoblasts, pericytes, and 
pre-adipocytes. In fact, in these mixed cell populations 
only a small proportion (approx. 1%) of bone marrow 
cells are progenitors or stem cells suitable for cardiac 
regeneration purposes (1). Among them, hematopoietic 
and mesenchymal stromal cells (MSCs), other mono-
nuclear cells, CD34+ cells, CD133+ cells home in the 
bone marrow. However, unselected bone marrow cells 
did not substantiate breakthrough regenerative effect in 
clinical scenario. 
Mesenchymal stromal cells (MSCs) are multipotent 
stem cells, and apart from bone marrow, they can be 
found in several organs indicating their importance in 
tissue regeneration in general. Pre-clinical studies re-
ported their reparative capacity uniquely, regardless of 
their origin. MScs are immune privileged, less recogni-
zed by the host immune system and have immunosup-
pressive characters; for those reasons, they are pre-
ferred for allogeneic cell therapy. MSCs are known to 
secrete hundreds of proteins, such as growth factors 
(VEGF, HGF, IGF-1), anti-apoptotic and anti-infl am-
matory mediators, SFRP-2, angiogenin, cystatin, all of 
them are essential in cardiac regeneration (2, 3). 
The broad use of unselected or selected bone marrow 
cells is limited by several factors, such as the extensive 
cell culture conditions and the several passages that 
are necessary to reach the required number of selec-
ted cells, as well as their usual autologous origin (sick 
cells from sick patients), or the narrow time window 
between harvesting and clinical application. In order to 
overcome the disadvantages of bone marrow derived 
MSCs, the use of adipose tissue-derived mesenchymal 
or stromal cells (ADSCs) were also explored in sub-
sequent clinical trials. The usual source of the ADSCs 
is the abdominal adipose tissue, gained by liposuction. 
The ultimate advantage of ADSCs is the possibility to 
be produced under sterile GMP conditions, as ATMP 
(Advanced Therapy Medicinal Product), a “regenerative 
substance”, ready to use with long shelf life (commer-
cial off-the-shelf product). Furthermore, ASCs grow fa-
ster than MSCs during culture expansion. 
Other potential sources of cardiomyogenic cells that ex-
hibit MSC properties have also been identifi ed. Those 
includes endometrial regenerative cells, mesenchymal 
cells derived from menstrual blood, and those derived 
from endometrium. These cells typically express sur-
face markers such as CD29 and CD105, suggesting 
MSC properties and they can exert cardiomyocyte-like 
action potentials. 
The discovery of the cardiac stem cells (CSCs) and car-
diosphere-derived cells (CDCs) (4) that are positive for 
self-renewing c-kit and clonogenic, opened up new di-
rections in cardiac regenerative therapy and two phase 
I trials were initiated using those cells. The SCIPIO (5) 
and the CADUCEUS (6) trials were designed to inves-
tigate the effect of CSCs and CDCs in patients with su-
bacute myocardial infarction and ischemic HF, resepec-
tively. The SCIPIO trial demonstrated that intracoronary 
infusion of autologous CSCs led to better left ventricu-
lar ejection fraction in a small subset of patients (5) but 
CADUCEUS showed no effects on the primary endpoint 
(systolic function), although scar dynamics and the ability 
of the regenerative muscle to distend did improve (6). 
Beside searching of new therapeutic cell types, further 
cell processing methods were developed to enhance 
the homing, vascularizing and muscle regenerative ca-
pacity of the injected cells. The Ixmyelocel-T composite 
is an expanded bone marrow mononuclear cell mixt-
ure, with about 200x higher number of M2 macropha-
ges (anti-infl ammatory cells) and 50x higher number 
of CD90+ BM-MSCs (regenerative cells). The Ixmyel-
ocel-T Phase 2b randomized study was a part of the 
ixCELL-DCM trial, and included patients with ischemic 
dilated cardiomyopathy with an ejection fraction ≤35%. 
The percutaneous transendocardial delivery of Ixmyel-
ocel-T led to signifi cant reduction of clinical cardiac ad-
verse events, without affecting the ejection fraction (7). 
The C-Cure cells were autologous bone-marrow origin 
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MSCs, subjected to a cardiogenic cocktail to trigger 
the expression and nuclear translocation of cardiac 
transcription factors in order to achieve lineage specifi -
cation and maintaining clonal proliferation (8). After 3 
passages, only cells with >2-fold induction of nuclear 
MEF2c were selected for the clinical administration (8). 
Cell therapy with the C-Cure cells led to a signifi cant 
improvement in ejection fraction in a small cohort, while 
the larger randomized CHART-1 trial could not confi rm 
those early results (9). 
Application mode of cell therapy 
in HF patients
The various mode of applications, the advantages and 
disadvantages of the percutaneous intracoronary, int-
ramyocardial and surgical direct intramyocardial delive-
ry of cells or other regenerative substances have been 
previously summarized (10). Briefl y, percutaneous int-
racoronary cell delivery represents the easiest way to 
transplant cells into the heart via the coronary arteries, 
allowing unlimited amounts of cells or injection volume, 
albeit with rapid wash-out and less effi cient biodistribu-
tion, with consequently less homing of the cells. Percu-
taneous intramyocardial injection of cells leads to more 
exact spatial cell transplantation to the ischemic area, 
with less washout; however, the amount of the injec-
table cells is limited, and the procedure is more comp-
licated and costly (11). Surgical direct intramyocadial 
injection allows direct delivery and the visualization of 
the cell transplantation into the heart, however, it requi-
res open heart surgery and randomization and blinding 
in such clinical trials is diffi cult. Nevertheless, patients 
with ischemic HF have often multiple coronary lesions, 
previous myocardial infarction, or bypass surgery, or 
occluded vessels. For that reason, the direct intramyo-
cardial delivery mode of therapeutic cells is presumably 
more appropriate as the intracoronary delivery method.
Clinical studies
Up to now, more than two hundred small or medium-lar-
ge cell-based cardiac regeneration studies are registe-
red in clinicaltrials.gov home page, involving patients 
with ischemic HF. Several of them have not even star-
ted yet, or prematurely stopped due to lack of sponsor 
or slow recruiting rate. 
Table 1 lists the completed and published clinical cell- 
based therapy studies including patients with chronic 
ischemic HF (5–9, 12–41). Few studies with either int-
ravenous or surgical intramyocardial delivery modes 
were not included, due to small number of such studi-
es and patients. The Table 1 shows the delivery mode, 
study design (randomized or not), the number of the 
treated and control patients, and the baseline and fol-
low-up ejection fraction of the treated patients, in case 
these values were published. 
Majority of the studies includes patients with low ejecti-
on fraction (<40%). Eight of the 35 listed studies (22.9%) 
includes 516 of 1962 patients (26.3%) used the intraco-
ronary delivery mode, while the others used the percu-
taneous intramyocardial cell transplantation. 
Four intracoronary cell trials (3 of them from the Frank-
furt group) demonstrated signifi cant improvement of the 
left ventricular function in patients with ischemic HF trea-
ted with cells. From the 10 randomized intramyocardial 
cell therapy studies, where baseline and follow-up LV EF 
were reported, 8 trials showed signifi cantly better LV EF 
in the cell-therapy group as compared to the controls. 
However, the last 3 largest randomized trials (Ixmyelo-
cel-T Phase 2b, CHART-1 and ATHENA) could not de-
monstrate signifi cantly improved LV performance after 
cell therapy compared to controls, albeit signifi cantly 
less clinical adverse event were observed in the Ixmyel-
ocel-T trial and the quality of life was improved in the AT-
HENA study in patients receiving cell treatment (7, 9, 38). 
Meta-analyses
To overcome the major obstacles of cardiac cell therapy 
trials, namely small size with slow patient recruitment in 
a relevant time frame, meta-analyses of the published 
data have been performed to reach the required sta-
tistical power. From the pooled data, the average EF 
increase with cell therapy has been found to be from 
–0.16% to 5.4% with variability across studies in popu-
lation size, design, and method of EF evaluation (42, 
43). In all, little to moderate therapeutic benefi t from 
cell therapy has been reported in terms of survival or 
cardiovascular-related adverse events, but the largest 
meta-analyses were able to identify persistent improve-
ment in other clinical endpoints and LV function (Fisher 
2015) (43). 
The major drawback of these meta-analyses is the high 
heterogeneity between included trials, and that they 
possibly exclude relevant studies reporting median va-
lues with non-normally distributed data. The gold stan-
dard type of meta-analysis is based on the individual 
patient data (IPD), the consistent use of unique defi ni-
tions and the transparency of data sets, and can ana-
lyze subgroups for features that may be in association 
with cell therapy effectiveness.
The initial IPD meta-analysis was ACCRUE (Meta-Ana-
lysis of Cell-based CaRdiac studies), which published 
12 randomized studies of intracoronary cell administra-
tion in patients with recent AMI showed no effect of cell 
therapy on LVEF or clinical outcomes, and found no 
predictors or patient characteristics associated with the 
benefi t of intracoronary cell therapy (45, 46). The IPD 
meta-analysis of trials involving patients with ischemic 
HF is currently ongoing.
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Further directions, secretomes, exosomes 
and non-coding RNAs
One of the major problems with the cardiac cell thera-
py is the low cell retention rate, and rapid distribution 
of the cells in remote organs (47). In contrast, almost 
all clinical studies suggested some benefi t of the cell 
therapy, either in improvement of clinical symptoms, or 
reduction of adverse events or increase in LV function. 
The reason for the benefi t of the cells in light of these 
fi ndings may be attributed to the secretion of paracri-
ne-signaling factors that exert promotional effects on 
the myocardium and vasculature. 
According to the “paracrine hypothesis”, different stem 
cell types secrete tissue regenerative proteins and small 
molecules, like chemokines, cytokines, and growth fac-
tors. Several of these factors are recognized to improve 
cardiovascular function in acute or chronic cardiac tis-
sue injury (48). The paracrine history paved the way to 
cell-free therapy approaches, e.g. cardiac regeneration 
without cell transplantation.
Furthermore, all cell types, also the injected stem cells 
secrete extracellular membrane vesicles such as exo-
somes and microparticles. Both of them are present 
naturally in all biological fl uids, and store materials, 
including noncoding (nc)RNAs (miRNAs, lncRNAs), 
lipids and proteins. MicroRNAs are short, approxima-
tely 22 nucleotides long, and long noncoding RNAs 
are longer (>200 nucleotide), noncoding transripts that 
are post-transcriptional regulators of gene expressi-
ons and thus cell function. Dysfunction of ncRNAs has 
been associated with pathologies, including CAD and 
HF. Many of the ncRNAs are remarkably stable outside 
the cells, in the extracellular environment. The circula-
ting non-coding RNAs are suggested to have paracri-
ne mediator function in cardiac repair, involving several 
interacting cellular network and biological pathways to 
reduce cardiac infl ammation, fi brosis and remodeling, 
and promote vascular growth and tissue regeneration, 
regulate survival of cells, and recruit and activate in situ 
stem and progenitor cell populations (Table 2) (48–50). 
Accordingly, a new era has evolved in the cardiac rege-
neration fi eld, to replace the cells with various factors 
that regulate distinct pathogenic cell functions at mole-
cular level. 
In conclusion, cardiac cell therapy for patients with 
ischemic HF is still a promising option to reduce disea-
se-related morbidity and mortality. In order to enhance 
the success of cardiac regeneration therapy, new mo-
lecular approaches using specifi c protein and ncRNA 
based factors are being assessed to achieve breakt-
hrough in cardiac repair. 
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